First promising results

Transgene is developing TG6002 for the treatment of several solid tumors, such as gastro-intestinal adenocarcinoma (stomach, pancreas and colon). Phase I interim results demonstrate that after IV infusion, TG6002 was detected in the tumor and induced the production of 5-FU. No major SAE have been observed.

  Poster presented at ESMO 2021 

Attacking the tumor on several fronts

TG6002 combines several mechanisms of action to:

• directly and selectively destroy the cancer cells (oncolysis) by causing immunogenic cell death;
• induce an immune response,, following the release of antigens during the oncolysis;
• allow the production of chemotherapy (5-FU), directly in the tumor..

Ongoing clinical trials